Schinke T and Karsenty G |
Vascular calcification--a passive process in need of inhibitors. |
2000 |
Nephrol. Dial. Transplant. |
pmid:10978374
|
Lorenzo J |
Interactions between immune and bone cells: new insights with many remaining questions. |
2000 |
J. Clin. Invest. |
pmid:10995785
|
Teng YT et al. |
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. |
2000 |
J. Clin. Invest. |
pmid:10995794
|
Børset M et al. |
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. |
2000 |
Blood |
pmid:11001907
|
Kobayashi Y et al. |
Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. |
2000 |
J. Bone Miner. Res. |
pmid:11028444
|
Zhang YH et al. |
Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. |
2001 |
J. Biol. Chem. |
pmid:11032840
|
Kaneda T et al. |
Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. |
2000 |
J. Immunol. |
pmid:11035059
|
Fata JE et al. |
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. |
2000 |
Cell |
pmid:11051546
|
Miyamoto N et al. |
Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. |
2000 |
J. Orthop. Res. |
pmid:11052502
|
Kinpara K et al. |
Osteoclast differentiation factor in human osteosarcoma cell line. |
2000 |
J Immunoassay |
pmid:11071251
|
Kong YY et al. |
Osteoprotegerin ligand: a regulator of immune responses and bone physiology. |
2000 |
Immunol. Today |
pmid:11071528
|
Sakuma Y et al. |
Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. |
2000 |
Infect. Immun. |
pmid:11083800
|
Riggs BL |
The mechanisms of estrogen regulation of bone resorption. |
2000 |
J. Clin. Invest. |
pmid:11086020
|
Lee ZH et al. |
Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. |
2000 |
Mol. Pharmacol. |
pmid:11093794
|
Takami M et al. |
Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. |
2000 |
Endocrinology |
pmid:11108286
|
Gori F et al. |
The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. |
2000 |
Endocrinology |
pmid:11108292
|
Miyamoto T et al. |
An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. |
2000 |
Blood |
pmid:11110710
|
|
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. |
2000 |
Bone |
pmid:11113385
|
Takayanagi H et al. |
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. |
2000 |
Nature |
pmid:11117749
|
Mancini L et al. |
Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:11118297
|